LGND

286.9200.01%
PJ

Paul J. Hadden

Senior Vice President of Investments & Business Development

Mr. Paul J. Hadden serves as Senior Vice President of Investments and Business Development at Ligand Pharmaceuticals Incorporated. He served as a Partner at Healthcare Royalty Partners since April, 2018. He runs the firm’s European operations. Prior to this, he was a Managing Director at the firm since June 1, 2015. He focuses on firm's business development and transaction origination activities. He previously served as a Principal at the firm. Mr. Hadden joined the firm in 2007 as a Senior Associate. He is responsible for helping lead the firm's university and non-profit business development efforts, in addition to working with public and private companies seeking capital. He was a Vice President at the firm since January 2008. Mr. Hadden was a Principal of The Frankel Group LLC. While at The Frankel Group from 2001 to 2007, he advised biotechnology, pharmaceutical, and generic clients on business strategy, completing many projects focused on commercial/market assessments, sales forecasting, marketing strategies, and due diligence. Mr. Hadden was responsible for managing multiple teams of consultants and performing primary and secondary research. He worked at New York-Presbyterian Hospital as a Senior Financial Analyst providing financial planning support to the program development and clinical services division. He has over a decade of experience investing in and advising biotechnology and pharmaceutical companies. Mr. Hadden serves as a Director of Helomics Corporation. Mr. Hadden served as a Director of Suneva Medical, Inc. until August 4, 2016. He is a board observer of Cardiorentis AG. Mr. Hadden holds an M.P.H. from the Yale School of Public Health and an A.B. from the Yale College.

Positions